KLK4 and hereditary angioedema: Until 2020, when the kallikrein antagonist lanadelumab became available, the most common treatment for HAE-C1INH long-term prophylaxis (LTP) in Italy was danazol and stanazolol, two synthetic attenuated androgens (AA), which can predispose to cardiovascular and metabolic complaints (1).